Biogen, Inc. (BIIB)
195.50
+4.30
(+2.25%)
USD |
NASDAQ |
Feb 12, 16:00
195.67
+0.17
(+0.09%)
After-Hours: 20:00
Biogen Cash from Investing (Quarterly) : -1.232B for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -- |
| Merck & Co., Inc. | -- |
| AbbVie, Inc. | -- |
| Stoke Therapeutics, Inc. | 9.094M |
| Alnylam Pharmaceuticals, Inc. | 501.11M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 511.90M |
| Cash from Financing (Quarterly) | -137.00M |
| Free Cash Flow | 1.969B |
| Free Cash Flow Per Share (Quarterly) | 2.738 |
| Free Cash Flow to Equity (Quarterly) | 334.20M |
| Free Cash Flow to Firm (Quarterly) | 460.64M |
| Free Cash Flow Yield | 6.86% |